Want to see AU:NUZ full AI Analyst Report?
Top Page
Pharmaust Limited
(Sydney:NUZ)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.06
â–Ľ(-41.00% Downside)
Action:Downgraded
Date:08/27/26
The score is primarily held down by weak financial performance (zero recent revenue, large ongoing losses, and heavy cash burn), with additional pressure from bearish technical positioning (price below key moving averages and negative MACD). Valuation is also constrained by a negative P/E (loss-making) and no dividend yield support.
Positive Factors
Improved capitalization
The substantial increase in equity and assets gives Pharmaust a larger financial cushion than it had in 2025. Although losses remain significant, stronger capitalization can improve resilience, support ongoing development activities, and provide more flexibility in managing future funding needs.
Negative Factors
Revenue has fallen to zero
The absence of reported revenue across three consecutive years leaves Pharmaust without demonstrated commercial traction in the period covered. This weakens the foundation for self-funded growth, limits operating leverage, and makes future progress more dependent on successful commercialization or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved capitalization
The substantial increase in equity and assets gives Pharmaust a larger financial cushion than it had in 2025. Although losses remain significant, stronger capitalization can improve resilience, support ongoing development activities, and provide more flexibility in managing future funding needs.
Read all positive factors
Pharmaust Limited (NUZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$49.41M
Dividend YieldN/A
Average Volume (3M)560.86K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth47.31%
CountryAU
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding784,215,600
10 Day Avg. Volume589,769
30 Day Avg. Volume560,858
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.87
Price to Sales (P/S)2.08
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.20Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmaust Limited Business Overview & Revenue Model
Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate i...
How the Company Makes Money
null...
Pharmaust Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.59M | 0.00 | 0.00 | 2.82M | 3.38M |
| Gross Profit | 17.59M | 0.00 | -1.64K | -929.53K | -223.52K |
| EBITDA | -27.75M | -18.48M | -9.45M | -9.45M | -1.30M |
| Net Income | -10.72M | -16.59M | -9.03M | -9.03M | -1.71M |
Balance Sheet | |||||
| Total Assets | 23.70M | 4.36M | 11.12M | 6.13M | 6.13M |
| Cash, Cash Equivalents and Short-Term Investments | 12.71M | 4.18M | 9.72M | 2.71M | 2.71M |
| Total Debt | 3.31M | 0.00 | 0.00 | 1.05M | 1.05M |
| Total Liabilities | 10.97M | 1.54M | 896.61K | 2.24M | 2.23M |
| Stockholders Equity | 12.73M | 2.82M | 10.23M | 3.89M | 7.84M |
Cash Flow | |||||
| Free Cash Flow | -15.08M | -14.29M | -5.17M | -1.60M | -1.38M |
| Operating Cash Flow | -15.07M | -14.29M | -5.17M | -1.56M | -1.33M |
| Investing Cash Flow | -8.22K | -21.55K | -1.17M | -34.93K | -43.38K |
| Financing Cash Flow | 23.51M | 8.76M | 13.34M | 1.89M | 770.99K |
Pharmaust Limited Technical Analysis
Positive
0.10
Price Trends
0.06
Positive
0.07
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
59.14
Neutral
62.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NUZ, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.14 is Neutral, neither overbought nor oversold. The STOCH value of 62.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NUZ.
Pharmaust Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
46 Neutral | AU$166.88M | -1.81 | -1189.87% | ― | 53.78% | -206.24% | |
45 Neutral | AU$71.50M | -9.86 | -44.93% | ― | ― | 25.27% | |
43 Neutral | AU$110.08M | -7.14 | 84.67% | ― | ― | 42.51% | |
42 Neutral | AU$67.79M | -0.85 | -98.86% | ― | ― | -27.73% | |
40 Underperform | AU$49.41M | -3.83 | -102.07% | ― | ― | 47.31% |
* Healthcare Sector Average
AU:NUZ
Pharmaust Limited
0.06
-0.08
-56.34%
AU:PAR
Paradigm Biopharmaceuticals
0.28
0.02
5.77%
AU:IMM
Immutep Ltd
0.05
-0.18
-79.57%
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
62.50%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.11
-84.44%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
-0.11
-22.92%
Pharmaust Limited Corporate Events
NIH Backs Neurizon’s NUZ-001 ALS Access Program With Multimillion-Dollar Grant
Sep 9, 2026
Neurizon Therapeutics has secured participation in a multimillion-dollar, multi-year NIH-funded Expanded Access Protocol that will allow up to 200 people in the U.S. living with ALS, who are ineligible for clinical trials, to receive its lead inve...
Neurizon names seasoned pharma executive Chris Bremer as CEO ahead of key ALS trial readout
Sep 6, 2026
Neurizon Therapeutics has appointed Dr Chris Bremer as Chief Executive Officer, effective 1 October 2026, as the company advances its lead ALS candidate NUZ-001 through a registrational Phase 2/3 trial. Bremer will initially serve as CEO without j...
Neurizon Therapeutics Expands ASX Quoted Share Base
Aug 26, 2026
Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,116,092 ordinary fully paid shares under the code NUZ.The new securities, issued on August 26, 2026, arise from the exercise or conversion of existing options or other convert...
Neurizon Therapeutics files ASX governance disclosure for 2026
Aug 25, 2026
Neurizon Therapeutics Limited has lodged its corporate governance statement and completed Appendix 4G for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules. The statement, approved by the board as at 25 August 202...
Neurizon Therapeutics Narrows Loss and Strengthens Balance Sheet in 2026
Aug 25, 2026
Neurizon Therapeutics Limited has reported a sharply improved financial position for the year ended 30 June 2026, despite remaining loss-making. Other income surged by 844.2% to $17.77 million, helping cut the after-tax loss attributable to owners...
Neurizon Therapeutics Issues Large Tranche of Unquoted Incentive Securities
Aug 24, 2026
Neurizon Therapeutics Limited has notified the market of the issuance of a substantial tranche of unquoted equity securities under its employee incentive scheme. The company will issue more than 14 million performance rights and approximately 8 mi...
Neurizon strengthens Elanco alliance with appointment of new Board observer
Aug 13, 2026
Neurizon Therapeutics has appointed Dr. Steve Nanchen, Senior Advisor for External Innovation at Elanco Animal Health, as a non-voting Board Observer, reinforcing the strategic ties between the two companies. The move follows Neurizon’s excl...
Neurizon accelerates ALS trial and secures supply deal as funding base strengthens
Jul 31, 2026
Neurizon reported a strong June quarter marked by rapid clinical progress in its NUZ‑001 program within the Phase 2/3 HEALEY ALS Platform Trial, expanding Regimen I from 160 to 250 participants while maintaining statistical power and funding...
Neurizon Secures $17.5m Non-Dilutive R&D Financing to Fund ALS Trial
Jul 31, 2026
Neurizon Therapeutics has entered a strategic RD financing facility of up to $17.5 million with the Dare Capital Loan Fund, secured solely against its Australian RD Tax Incentive refunds. An initial drawdown of about $8 million tied to the FY2026 ...
Neurizon to Outline ALS Trial Progress and NUZ-001 Strategy at Melbourne Investor Briefing
Jul 29, 2026
Neurizon Therapeutics Limited has scheduled an investor briefing in Melbourne to present recent clinical, operational and corporate achievements, underscoring progress in its late-stage development pipeline for neurodegenerative disease therapies....
Neurizon director Marcus Hughes lifts stake with June share purchases
Jul 1, 2026
Neurizon Therapeutics Limited has reported a change in the shareholdings of director Marcus Hughes, reflecting additional acquisitions of fully paid ordinary shares across several transactions in late June 2026. The purchases, made both directly a...
Neurizon Therapeutics Plans Equity Placement of 461,538 Shares
Jun 30, 2026
Neurizon Therapeutics Limited has notified the ASX of a proposed placement of up to 461,538 ordinary fully paid shares, with an expected issue date of 22 September 2026. The additional equity issuance underscores the company’s ongoing need f...
Neurizon options lapse as 5 million NUZAP securities expire unexercised
Jun 29, 2026
Neurizon Therapeutics Limited has confirmed the cessation of 5,000,000 NUZAP options, which were due to expire on 28 June 2026 with an exercise price of $0.3325. The options lapsed without being exercised, resulting in a reduction of the company&#...
Neurizon strengthens NUZ-001 ALS case with new mechanistic data at BIO 2026
Jun 23, 2026
Neurizon Therapeutics has unveiled new preclinical mechanism-of-action data for its lead ALS candidate NUZ-001, to be presented at the BIO International Convention 2026, reinforcing the drug’s role as a multi-pathway modulator of protein hom...
Neurizon Therapeutics Seeks ASX Quotation for 9.7 Million New Shares
Jun 19, 2026
Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,655,460 new ordinary fully paid shares under code NUZ, with an issue date of 19 June 2026. The new securities arise from the exercise or conversion of existing options or othe...
Neurizon Secures Long-Term Elanco Supply Deal for Lead ALS Drug NUZ-001
Jun 16, 2026
Neurizon Therapeutics has signed a long-term supply agreement with Elanco Animal Health to secure access to Good Manufacturing Practice-grade monepantel, the active ingredient in its lead ALS therapy candidate NUZ-001, for an initial five-year ter...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.